10-05-2025
Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities
In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a price target of $40.00. The company's shares closed today at $9.90.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and Evolus. According to TipRanks, Ear has an average return of 0.0% and a 38.83% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cartesian Therapeutics with a $36.80 average price target.
RNAC market cap is currently $263.3M and has a P/E ratio of -0.20.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RNAC in relation to earlier this year. Last month, TIMOTHY A SPRINGER, a Director at RNAC bought 149,075.00 shares for a total of $1,521,840.87.
